Download A4Medicine Mobile App

Empower Your RCGP AKT Journey: Master the MCQs with Us! 🚀

A4Medicine

A4Medicine: Your comprehensive, fully referenced educational resource for primary care clinicians worldwide.

Your Primary Care Knowledge Hub

A4Medicine your path to primary care
exams success and safe practice!.

A4Medicine

Find It Fast on A4Medicine: Charts, Tables, MCQs, and Webinars for Medical Mastery!

    Dive into Charts, Engage in Webinars, Embrace Knowledge through Books, and Master Your Skills with MCQs at A4medicine!

    Unlock the Power of Knowledge with us

    Unlock the Power of Knowledge with us

    600+ Concise Charts and Counting, with New Content Unleashed!

    Join the Preferred Choice of 3000+ Primary Care Clinicians

    Join the Preferred Choice of 3000+ Primary Care Clinicians

    A4Medicine, Where Expertise Meets Community!

    Supercharge Your AKT Journey

    Supercharge Your AKT Journey

    1500+ RCGP AKT Questions ready to practice and More!

    Unleash the Power of Trust

    Unleash the Power of Trust

    A4Medicine, Where Every Chart and AKT Question is Backed by Verifiable References!

    Discover the Incredible Features of A4Medicine  Unleash the Power of Knowledge!

    choose the right option to join A4medicine

    WHY YOU SHOULD JOIN A4MEDICINE

    With a subscription to A4Medicine, clinicians gain access to a vast library of charts, books, webinars, and AKT MCQs (Multiple Choice Questions) that cover essential topics in primary care. These resources are meticulously crafted to provide valuable insights, evidence-based knowledge, and practical guidance.

    GuideBook

    The popular Visual Guidebook of Basic and Essential General Practice covers over 200 common topics in primary care using flowcharts from the website A4Medicine Visual Guidebook of Basic and Essential General Practice' covers up two hundred plus common topics in primary care using A4 Charts.

    Webinar

    A4Medicine offers medical educational webinars, conducted by domain specialists and specifically designed for primary care, utilizing the Zoho Webinar platform. These webinars offer impartial, balanced guidance from experts, completely free from pharmaceutical influence.

    Charts

    We provide over 650 medical charts which Covering 650 plus medical topics in form of A4 Charts. Adding New Charts Regularly Source/References Information also provided Cover one topic in each chart Decluttered and simplified Concise, comprehensive and to the point Up to date and evidence-based

    Visual Guidebook Of Basic And Essential General Practice & Family Medicine!
    Just For £65
    Essentials Of Cancer Medicine In Primary Care
    Just For £40
    PARAMEDICS GUIDE TO PRIMARY CARE : A SIMPLIFIED APPROACH BY A4MEDICINE
    Just For £35

    View  Latest Charts

    Female infertility is a multifaceted issue that can arise from various underlying causes. The primary categories of female infertility include ovulatory disorders, tubal factors, endometriosis, and other medical conditions. Each of these categories encompasses specific conditions that can significantly impact a woman's ability to conceive.



    Causes of Female Infertility

    Category Description Examples
    Ovulatory Disorders Conditions affecting the release of eggs from the ovaries, responsible for ~25-40% of infertility cases. - Polycystic Ovary Syndrome (PCOS)
    - Hypothalamic Dysfunction (due to stress, weight changes, etc.)
    - Premature Ovarian Insufficiency (POI)
    - Hyperprolactinemia (high prolactin levels)
    Tubal Factors Blockage or damage to the fallopian tubes, preventing sperm and egg from meeting, accounts for ~15-20% of cases. - Pelvic Inflammatory Disease (PID)
    - Previous surgeries causing adhesions
    - Congenital tubal abnormalities
    Endometriosis Growth of endometrial-like tissue outside the uterus, causing inflammation, adhesions, and anatomical distortions. - Pelvic adhesions
    - Tubal blockages
    - Ovulatory dysfunction due to endometrial lesions
    Uterine and Cervical Factors Issues with the structure or function of the uterus or cervix that interfere with sperm passage or implantation. - Uterine fibroids
    - Congenital uterine anomalies (e.g., septate or bicornuate uterus)
    - Cervical stenosis
    - Poor cervical mucus quality
    Other Medical and Endocrine Conditions Systemic conditions that disrupt reproductive hormones and cycles. - Thyroid disorders (e.g., hypothyroidism, hyperthyroidism)
    - Diabetes
    - Autoimmune disorders (e.g., lupus)
    Genetic or Chromosomal Abnormalities Certain genetic conditions that impact egg production, hormone levels, or reproductive anatomy. - Turner Syndrome (45,X)
    - Fragile X Premutation
    - Kallmann Syndrome (a rare genetic condition causing hypothalamic dysfunction)
    Unexplained Infertility Cases where no clear cause is identified after thorough evaluation, ~10-20% of infertility cases. - May involve subtle issues such as mild hormonal imbalances or immune factors
    Lifestyle and Environmental Factors External factors affecting fertility, often related to overall health and lifestyle. - Age (fertility declines after age 35)
    - Weight (significantly underweight or overweight)
    - Substance use (e.g., smoking, alcohol)
    - Exposure to environmental toxins



    Ovulatory disorders account for approximately 25% of infertility cases, with conditions such as Polycystic Ovary Syndrome (PCOS) being prevalent . Tubal factors, often resulting from pelvic inflammatory disease or previous surgeries, can also significantly impact fertility . Understanding these causes allows clinicians to tailor their approach to each patient effectively.


    • Thorough Evaluation is Key: A comprehensive assessment, including medical history, physical examination, and diagnostic tests, is essential for identifying the underlying causes of infertility. Hormonal assessments and imaging studies are critical components of this process.


    • Targeted Management Based on Cause: Management should be tailored to the specific diagnosis. Ovulatory disorders may benefit from lifestyle changes and medications, while tubal factor infertility may require surgical intervention or assisted reproductive technologies (ART).


    • Importance of Specialist Referral: Timely referral to a fertility specialist or reproductive endocrinologist is essential, especially for cases requiring advanced interventions. Collaboration with specialists ensures patients receive the most appropriate care for complex infertility issues.


    • Evidence-Based Approach: Staying updated on the latest evidence-based guidelines enables primary care clinicians to provide optimal initial care and recognize when specialist input is necessary.





    1. **Abebe, M., Afework, M., & Abaynew, Y.** (2020). Primary and secondary infertility in Africa: systematic review with meta-analysis. *Fertility Research and Practice, 6*(1). [https://doi.org/10.1186/s40738-020-00090-3](https://doi.org/10.1186/s40738-020-00090-3)
    2. **Abrão, M., Muzii, L., & Marana, R.** (2013). Anatomical causes of female infertility and their management. *International Journal of Gynecology & Obstetrics, 123*(S2). [https://doi.org/10.1016/j.ijgo.2013.09.008](https://doi.org/10.1016/j.ijgo.2013.09.008)
    3. **Boltz, M., Sanders, J., Simonsen, S., & Stanford, J.** (2017). Fertility treatment, use of in vitro fertilization, and time to live birth based on initial provider type. *The Journal of the American Board of Family Medicine, 30*(2), 230-238. [https://doi.org/10.3122/jabfm.2017.02.160184](https://doi.org/10.3122/jabfm.2017.02.160184)
    4. **Dhananjaya, S., Madhu, K., & Amiti, A.** (2014). Role of diagnostic hysterolaparoscopy in evaluation of primary and secondary infertility. *Journal of Evolution of Medical and Dental Sciences, 3*(9), 2194-2207. [https://doi.org/10.14260/jemds/2014/2126](https://doi.org/10.14260/jemds/2014/2126)
    5. **Hinton, L., Kurinczuk, J., & Ziebland, S.** (2012). Reassured or fobbed off? Perspectives on infertility consultations in primary care: a qualitative study. *British Journal of General Practice, 62*(599), e438-e445. [https://doi.org/10.3399/bjgp12x649133](https://doi.org/10.3399/bjgp12x649133)
    6. **Kabadi, Y., & Harsha, B.** (2016). Hysterolaparoscopy in the evaluation and management of female infertility. *The Journal of Obstetrics and Gynecology of India, 66*(S1), 478-481. [https://doi.org/10.1007/s13224-016-0863-5](https://doi.org/10.1007/s13224-016-0863-5)
    7. **Khanuja, P., Sunny, J., & Pawar, S.** (2017). Study on infertility—etiology, medication therapy management, and outcomes at a tertiary care hospital. *International Journal of Infertility & Fetal Medicine, 8*(3), 106-112. [https://doi.org/10.5005/jp-journals-10016-1158](https://doi.org/10.5005/jp-journals-10016-1158)
    8. **Madhuri, N., Rashmi, H., Sujatha, M., & Dhanyata, G.** (2019). Role of diagnostic hysterolaparoscopy in the evaluation of female infertility. *International Journal of Research in Medical Sciences, 7*(5), 1531. [https://doi.org/10.18203/2320-6012.ijrms20191630](https://doi.org/10.18203/2320-6012.ijrms20191630)
    9. **Nida, .., Qureshi, M., Usman, H., Akram, A., Khan, S., Jawad, N., … & Bhutta, M.** (2022). A cross-sectional study on serum follicle stimulating hormone and luteinizing hormone in patients with anovulatory disorders with primary infertility. *PJMHS, 16*(12), 490-492. [https://doi.org/10.53350/pjmhs20221612490](https://doi.org/10.53350/pjmhs20221612490)
    10. **Nour-Eldein, H.** (2013). Family physicians’ attitude and practice of infertility management at primary care - Suez Canal University, Egypt. *Pan African Medical Journal, 15*. [https://doi.org/10.11604/pamj.2013.15.106.1762](https://doi.org/10.11604/pamj.2013.15.106.1762)
    11. **Palmer-Wackerly, A., Voorhees, H., D'Souza, S., & Weeks, E.** (2019). Infertility patient-provider communication and (dis)continuity of care: an exploration of illness identity transitions. *Patient Education and Counseling, 102*(4), 804-809. [https://doi.org/10.1016/j.pec.2018.12.003](https://doi.org/10.1016/j.pec.2018.12.003)
    12. **Stanford, J., Carpentier, P., Meier, B., Rollo, M., & Tingey, B.** (2021). Restorative reproductive medicine for infertility in two family medicine clinics in New England, an observational study. *BMC Pregnancy and Childbirth, 21*(1). [https://doi.org/10.1186/s12884-021-03946-8](https://doi.org/10.1186/s12884-021-03946-8)
    13. **Verma, K., & Baniya, G.** (2016). A comparative study of depression among infertile and fertile women. *International Journal of Research in Medical Sciences*, 3459-3465. [https://doi.org/10.18203/2320-6012.ijrms20162312](https://doi.org/10.18203/2320-6012.ijrms20162312)



    Infertility : Female causes

    Starting in September 2024, significant reforms to death certification laws in the UK will enhance the accuracy, quality, and scrutiny of mortality data. These updates aim to streamline the certification process while ensuring that key details about the cause of death are carefully reviewed and documented.


    One of the central changes includes the addition of medical examiners who will independently review each Medical Certificate of Cause of Death (MCCD), adding a level of verification to support attending practitioners and improve public health insights. The new MCCD format now has more detailed sections to record the chain of events leading to death and includes specific fields for information on ethnicity, maternal status, and any medical devices or implants.


    These updates will impact clinical practice by improving the precision of death reporting, providing crucial data for national and local health analysis, and ensuring a supportive process for families during bereavement. The following outlines the main changes and their implications for healthcare providers in the UK.



    Aspect Previous Practice New Practice (from 2024) Impact on Clinical Practice
    Mandatory Independent Review Only certain deaths required review by a Medical Examiner or Coroner All deaths in England and Wales must be reviewed by either a Medical Examiner or Coroner Ensures all deaths are independently reviewed, adding scrutiny and accuracy to the process
    Attending Practitioner Requirements Practitioner must have seen the patient within 28 days before or after death Practitioner only needs to have attended the patient at any point in their lifetime Easier for practitioners to complete MCCD, removing the need for recent visits
    Issuing Medical Certificate of Cause of Death (MCCD) GPs issued MCCDs independently MCCD is sent to Medical Examiner, who reviews the cause and receives patient records Practitioners must work with Medical Examiners and ensure patient records are accessible for review
    New MCCD Format Limited lines for cause of death; no fields for ethnicity, pregnancy, or devices Includes additional "line 1d" for cause of death, fields for ethnicity, pregnancy status, and medical devices More detailed recording enhances public health data and aligns with international standards
    Medical Examiner Signature Practitioner signs and sends MCCD directly to the registrar Medical Examiner adds their declaration to the MCCD before registrar submission Adds an extra layer of accountability and verification for causes of death
    Removal of 28-Day Rule Referral to coroner needed if patient not seen recently by GP Coroner referral no longer needed based on recent visits alone Simplifies MCCD process, reducing unnecessary coroner referrals
    Registration Timelines Death registration deadline was 5 days from the date of death 5-day limit now starts when registrar receives MCCD from Medical Examiner Aligns timelines with the review process, potentially allowing more time for accurate certification
    Exceptional Circumstances Coroner involvement required if attending practitioner unavailable Medical Examiner may issue MCCD if cause is known and natural; coroner issues form CN1B in these cases Supports timely certification if the attending practitioner is unavailable
    Electronic Certification Paper-based death certification Mandatory electronic death certification Streamlines the process, enabling faster data entry and reporting
    Cremation Form Changes Cremation Form 4 required in most cases Cremation Form 4 removed; new forms (1, 6, and 10) introduced Simplifies paperwork for cremation, reducing administrative burden on clinicians and families


    The 2024 changes to UK death certification laws aim to improve the accuracy, consistency, and transparency of death documentation. These reforms were driven by the need for more reliable mortality data to support public health analysis and policy. By introducing independent reviews from medical examiners, expanding the details recorded on the Medical Certificate of Cause of Death (MCCD), and implementing mandatory electronic certification, the system enhances data quality and provides better oversight.


    The addition of ethnicity, maternal status, and medical device information on the MCCD, as well as the removal of the 28-day rule, addresses gaps highlighted in recent years, especially during the COVID-19 pandemic. These updates enable more precise mortality records, support better care for bereaved families, and align the UK’s practices with international standards for greater public health benefits.


    Key Impact on GPs in the UK


    Aspect Change Impact on GPs
    Death Certificate Issuance GPs will no longer issue death certificates independently GPs must now work with Medical Examiners, who verify MCCDs before submission
    New Referral Process GPs or duty clinicians must contact relatives to gather information for Medical Examiner referral Adds a new step, requiring GPs to reach out to families, usually within 72 hours
    Sharing Information with Medical Examiners GPs must share the MCCD with a Medical Examiner before it’s sent to the Registrar Increases collaboration with Medical Examiners and introduces a step for verification
    Wider Pool of Practitioners for MCCDs Removal of the requirement to have seen the deceased within a specific timeframe More practitioners are eligible to complete MCCDs, easing issuance requirements
    Potential Increase in Administrative Work GPs may need new processes for referrals and information sharing Likely additional administrative tasks to handle referrals and coordinate with examiners
    Possible Delays in Death Registration Medical Examiner involvement may extend certification and registration timelines May result in longer processing times, especially during early stages of implementation
    Reduced Need for Coroner Referrals Coroner referrals no longer needed solely based on recent patient contact Streamlines process, reducing unnecessary referrals to the coroner



    The 2024 reforms to the UK death certification process, particularly the removal of Cremation Form 4, are expected to impact GP incomes due to the elimination of payments previously associated with the form. 


    1. Removal of Cremation Form 4:

      • Change: Cremation Form 4, which required a doctor’s certification for cremation cases, has been permanently removed for all deaths in England and Wales as of September 9, 2024.
      • Financial Impact: The removal of this form eliminates a long-standing source of additional income for GPs, especially for resident doctors who frequently completed these forms. GPs were typically compensated for each Cremation Form 4 completed, which represented a modest but steady income.


    Sharing Patient Records with Medical Examiners:

    • Change: GPs are now required to share relevant parts of the deceased patient’s medical records or a summary with the Medical Examiner.
    • Impact: This requires GPs to prepare and provide patient information in a timely manner, usually within 72 hours of the death, adding an administrative task. However, as most cases do not require a verbal discussion with the Medical Examiner, the administrative burden is partially managed, though still unpaid.

    New Obligations without Payment:

    • Change: Under the new system, doctors must declare any hazardous implants directly on the Medical Certificate of Cause of Death (MCCD), replacing what was previously documented on the cremation form.
    • Impact: This additional responsibility is considered a statutory obligation with no associated fee, adding unpaid administrative work for doctors.


    Transition to Mandatory Medical Examiner Review:

    • The requirement for all MCCDs to be reviewed by a Medical Examiner for cases not referred to a coroner adds another layer of review without direct compensation for GPs.
    • Impact: This change not only removes payments from cremation form fees but may also increase administrative workload, as GPs must prepare information for Medical Examiners without additional pay.

    No Requirement for Verbal Discussion:

    • Change: In most cases, GPs are not required to have a direct conversation with the Medical Examiner, as records or summaries typically suffice.
    • Impact: This limits time spent on discussions and may streamline the referral process, though the GP still needs to compile and provide relevant documentation for review.


    Timeframe for Referral:

    • Change: GPs or duty clinicians are expected to send the referral to the Medical Examiner typically within 72 hours of the death occurring.
    • Impact: This new timeframe creates an additional administrative deadline for GPs to meet. While it ensures prompt certification, it may increase pressure on GPs to complete records-sharing quickly, adding to their workload, particularly in busy practices or in cases where record compilation is time-consuming.


    Support from Medical Examiners for Complex Cases:

    • Change: Medical Examiners can assist GPs with complex cases, especially where coroner notification is necessary.
    • Impact: Although there’s no financial compensation involved, this support can reduce the administrative and procedural burden for GPs in challenging cases, ensuring that complex certifications are handled more accurately and efficiently.


    Nationwide and Permanent Change:

    • This change affects all GPs across England and Wales, marking a shift in an additional income source that many GPs previously had benefited from.

    • Impact: The nationwide reform means all practitioners will experience the same financial adjustments, with no flexibility or alternative income from the removed cremation form fees.


    References


    1. https://www.parkmedical.org.uk/2024/10/02/sept-2024-new-medical-examiner-changes-for-death-certificates/
    2. https://www.gov.uk/government/publications/changes-to-the-death-certification-process
    3. https://www.kctrust.co.uk/blog/revolutionising-death-certificates
    4. https://portcullis-surgery.co.uk/changes-to-the-death-certification-and-registration-process-effective-from-september-2024/
    5. https://www.nafd.org.uk/2024/09/09/death-certification-reforms-in-england-and-wales-go-live-just-after-midnight/
    6. https://www.gov.uk/government/publications/changes-to-the-death-certification-process/an-overview-of-the-death-certification-reforms
    7. https://www.england.nhs.uk/long-read/national-medical-examiners-guidance-for-england-and-wales/
    8. https://www.reddit.com/r/doctorsUK/comments/1fnlzwd/cremation_form_and_fee_removed_for_doctors/
    9. https://www.gov.scot/publications/funeral-expense-assistance-scotland-amendment-regulations-2024-business-regulatory-impact-assessment/
    10. https://www.gov.uk/government/collections/cremation-forms-and-guidance
    11. https://www.gov.uk/government/publications/medical-practitioners-guidance-on-completing-cremation-forms





    Death certification laws- 2024 Updates

    Vulvodynia is a complex and often misunderstood condition characterized by chronic vulvar pain without an identifiable cause. It can manifest as either provoked pain, which occurs upon touch or pressure, or unprovoked pain, which arises spontaneously. This condition significantly impacts the quality of life of affected individuals, leading to physical, psychological, and social challenges. The prevalence of vulvodynia is notable, with estimates suggesting that it affects approximately 8-12% of women, indicating a substantial public health concern that primary care clinicians must address (Cox & Neville, 2012; Kim et al., 2019).



    Category Details
    Definition Chronic vulvar pain lasting at least 3 months without an identifiable cause, potentially linked to multiple associated factors.
    Prevalence Affects up to 16% of women across diverse age groups and ethnicities, highlighting its significant impact as a public health concern.
    Symptoms - Burning sensation (🔥)
    - Sharp, knife-like pain (🔪)
    - Stinging (🦂)
    - Rawness or soreness (🧠)
    - Aching or throbbing (🔄)
    Classification - Localized Vulvodynia (e.g., Vestibulodynia)
    - Generalized Vulvodynia
    Etiology - Genetic Susceptibility (🧬)
    - Inflammatory Processes (🦠)
    - Neurological Sensitization (🧠)
    - Pelvic Floor Muscle Dysfunction (💪)
    Diagnosis Diagnosis of Exclusion - Rule out:
    - Infections (e.g., candidiasis, herpes)
    - Inflammatory conditions (e.g., lichen sclerosus)
    - Neoplastic or Neurologic disorders
    Pain Types - Provoked Pain: Triggered by touch or pressure
    - Unprovoked Pain: Spontaneous without external stimulus
    Impact on Life Affects physical, psychological, and social aspects of life, reducing quality of life for sufferers.
    Primary Care Role Early recognition and intervention are essential for effective management. Primary care providers should initiate the diagnostic process and guide treatment pathways.
    Management Approaches - Multimodal Treatment (includes cognitive-behavioral therapy and physical therapy)
    - Education about the condition
    - Psychological Support
    - Physiotherapy for symptom relief
    Psychosocial Aspects - Psychological distress and chronic stress are associated with symptom onset and severity.
    - History of trauma or abuse may increase the risk, highlighting the need for mental health assessments.
    Comorbid Conditions Conditions such as interstitial cystitis and fibromyalgia often coexist with vulvodynia, complicating the diagnosis and necessitating a comprehensive health evaluation.




    **Risk Factors for Vulvodynia:**

    1. **Biological Factors**
    - **Neurogenic Inflammation**: Increased nervous system sensitivity and hyperinnervation in the vulvar region, often due to chronic inflammation or injury, can lead to persistent pain【Barry et al., 2019; Tonc, 2023】.
    - **Hormonal Influences**: Fluctuations in estrogen levels can affect vulvar tissue sensitivity and increase pain perception【Sacinti, 2023】.
    - **Comorbid Conditions**: Disorders like interstitial cystitis, commonly seen alongside vulvodynia, can intensify symptoms and complicate diagnosis【Kahn et al., 2010; Reed et al., 2014】.

    2. **Psychological Factors**
    - **Mental Health History**: Anxiety, depression, or trauma, especially from sexual abuse, increases the risk for vulvodynia【Silva et al., 2023; Tribó et al., 2019】.
    - **Pain-Psychology Connection**: Psychological distress can amplify pain, contributing to vulvodynia's persistence【Tribó et al., 2019; Bergeron et al., 2014】.
    - **Comorbid Psychological Disorders**: High prevalence of anxiety and depression among vulvodynia patients complicates treatment【Thornton & Drummond, 2015; Sadownik, 2014】.

    3. **Social Factors**
    - **Adverse Experiences**: Childhood trauma and negative relationships increase susceptibility to chronic pain, potentially due to maladaptive coping【Sacinti, 2023; Bergeron et al., 2014】.
    - **Societal Stigma**: Stigma around sexual health and pain can cause isolation and delay treatment-seeking, worsening outcomes【Bergeron et al., 2014; Sadownik, 2014】.

    Understanding these multifactorial risk factors is crucial for effective management and patient support in cases of vulvodynia.


    **References:**

    1. Chisari, C., & Chilcot, J. (2017). The experience of pain severity and pain interference in vulvodynia patients: the role of cognitive-behavioural factors, psychological distress, and fatigue. *Journal of Psychosomatic Research, 93*, 83-89. https://doi.org/10.1016/j.jpsychores.2016.12.010
    2. Cohen-Sacher, B., Haefner, H., Dalton, V., & Berger, M. (2015). History of abuse in women with vulvar pruritus, vulvodynia, and asymptomatic controls. *Journal of Lower Genital Tract Disease, 19*(3), 248-252. https://doi.org/10.1097/lgt.0000000000000075
    3. Cox, K., & Neville, C. (2012). Assessment and management options for women with vulvodynia. *Journal of Midwifery & Women's Health, 57*(3), 231-240. https://doi.org/10.1111/j.1542-2011.2012.00162.x
    4. Khandker, M., Brady, S., Vitonis, A., MacLehose, R., Stewart, E., & Harlow, B. (2011). The influence of depression and anxiety on the risk of adult-onset vulvodynia. *Journal of Women’s Health, 20*(10), 1445-1451. https://doi.org/10.1089/jwh.2010.2661
    5. Kim, S., Kim, J., & Yoon, H. (2019). Sexual pain and IC/BPS in women. *BMC Urology, 19*(1). https://doi.org/10.1186/s12894-019-0478-0
    6. Paszkowski, T., & Baszak-Radomańska, E. (2021). Vulvodynia in prepubertal girls: diagnosis. *Ginekologia Polska.* https://doi.org/10.5603/gp.a2021.0190
    7. Patla, G., Mazur-Biały, A., Humaj-Grysztar, M., & Bonior, J. (2023). Chronic vulvar pain and health-related quality of life in women with vulvodynia. *Life, 13*(2), 328. https://doi.org/10.3390/life13020328
    8. Reed, B., Harlow, S., Sen, A., Edwards, R., Chen, D., & Haefner, H. (2012). Relationship between vulvodynia and chronic comorbid pain conditions. *Obstetrics and Gynecology, 120*(1), 145-151. https://doi.org/10.1097/aog.0b013e31825957cf
    9. Tersiguel, A., Bodéré, C., Schöllhammer, M., Postec, E., Quinio, B., Brenaut, E., & Miséry, L. (2015). Screening for neuropathic pain, anxiety, and other associated chronic pain conditions in vulvodynia: a pilot study. *Acta Dermato-Venereologica, 95*(6), 749-751. https://doi.org/10.2340/00015555-2053
    10. Torres-Cueco, R., & Nohales-Alfonso, F. (2021). Vulvodynia—it is time to accept a new understanding from a neurobiological perspective. *International Journal of Environmental Research and Public Health, 18*(12), 6639. https://doi.org/10.3390/ijerph18126639
    11. Barry, C., Matusica, D., & Haberberger, R. (2019). Emerging evidence of macrophage contribution to hyperinnervation and nociceptor sensitization in vulvodynia. *Frontiers in Molecular Neuroscience, 12.* https://doi.org/10.3389/fnmol.2019.00186
    12. Bergeron, S., Likes, W., & Steben, M. (2014). Psychosexual aspects of vulvovaginal pain. *Best Practice & Research Clinical Obstetrics & Gynaecology, 28*(7), 991-999. https://doi.org/10.1016/j.bpobgyn.2014.07.007
    13. Kahn, B., Tatro, C., Parsons, C., & Willems, J. (2010). Prevalence of interstitial cystitis in vulvodynia patients detected by bladder potassium sensitivity. *Journal of Sexual Medicine, 7*(2_Part_2), 996-1002. https://doi.org/10.1111/j.1743-6109.2009.01550.x
    14. Reed, B., Legocki, L., Plegue, M., Sen, A., Haefner, H., & Harlow, S. (2014). Factors associated with vulvodynia incidence. *Obstetrics and Gynecology, 123*(2), 225-231. https://doi.org/10.1097/aog.0000000000000066
    15. Sacinti, K. (2023). Is vulvodynia associated with an altered vaginal microbiota?: a systematic review. *Journal of Lower Genital Tract Disease, 28*(1), 64-72. https://doi.org/10.1097/lgt.0000000000000780
    16. Sadownik, L. (2014). Etiology, diagnosis, and clinical management of vulvodynia. *International Journal of Women's Health, 437.* https://doi.org/10.2147/ijwh.s37660
    17. Silva, V., Silva, G., Sousa, M., Pereira, R., Barbosa, A., & Lima, J. (2023). Physical and social repercussions generated in women with vulvodynia: a bibliographical review. *International Journal of Health Science, 3*(8), 2-5. https://doi.org/10.22533/at.ed.159382331016
    18. Thornton, A., & Drummond, C. (2015). Current concepts in vulvodynia with a focus on pathogenesis and pain mechanisms. *Australasian Journal of Dermatology, 57*(4), 253-263. https://doi.org/10.1111/ajd.12365
    19. Tonc, E. (2023). Immune mechanisms in vulvodynia: key roles for mast cells and fibroblasts. *Frontiers in Cellular and Infection Microbiology, 13.* https://doi.org/10.3389/fcimb.2023.1215380
    20. Tribó, M., Canal, C., Baños, J., & Robleda, G. (2019). Pain, anxiety, depression, and quality of life in patients with vulvodynia. *Dermatology, 236*(3), 255-261. https://doi.org/10.1159/000503321





    Vulvodynia

    Vaginismus is a complex and often misunderstood condition characterized by involuntary contractions of the pelvic floor muscles, which can hinder vaginal penetration and cause significant distress for affected women.


    The DSM-5 defines vaginismus as part of the broader category of Genito-Pelvic Pain/Penetration Disorder (GPPPD). This disorder encompasses difficulties with vaginal penetration, often accompanied by pain, fear, or marked tightening of the pelvic floor muscles.


    DSM-5 Definition of Vaginismus (as part of Genito-Pelvic Pain/Penetration Disorder)


    Genito-Pelvic Pain/Penetration Disorder includes persistent or recurrent difficulties in one (or more) of the following areas:

    1. Vaginal penetration during intercourse.
    2. Marked vulvovaginal or pelvic pain during vaginal intercourse or attempted penetration.
    3. Marked fear or anxiety about pain in anticipation of, during, or as a result of vaginal penetration.
    4. Marked tensing or tightening of the pelvic floor muscles during attempted vaginal penetration.

    Diagnostic Criteria:

    • The symptoms must cause significant distress or interpersonal difficulty.
    • The symptoms must be present for at least 6 months.
    • The symptoms cannot be better explained by a nonsexual mental disorder, a medical condition, or the effects of a substance or medication.


    Epidemiology

    • Prevalence is estimated at 1-7% of women worldwide, though exact figures are challenging to determine due to underreporting.
    • Most commonly affects women in their late teens to early 30s.
    • Women seeking Tx for sexual dysfunction: 21-48% (Eserdağ et al., 2021; Ferreira & Souza, 2012)


    Risk Factors


    Category Risk Factors
    Psychological Factors - Anxiety or fear related to sexual activity
    - History of sexual abuse or trauma
    - Negative attitudes or beliefs towards sex
    Physical Factors - Previous painful sexual experiences
    - Pelvic floor muscle dysfunction
    - Medical conditions (e.g., endometriosis, vulvodynia, vestibulodynia)
    Cultural/Religious Factors - Cultural or religious beliefs promoting negative views of sexuality
    Additional Organic Factors - Conditions reducing arousal or lubrication (e.g., diabetes, spinal cord injury, multiple sclerosis)
    Congenital Factors - Congenital genital malformations (e.g., paramesonephric duct abnormalities)



    Presentation


    Category Details
    Clinical Presentation - Involuntary spasm of vaginal muscles during penetration attempts (e.g., intercourse, exams, tampon use)
    - May occur with sexual intercourse, gynecological exams, or tampon insertion
    Classification - Primary (Lifelong) Vaginismus: No prior painless penetration experience
    - Secondary (Acquired) Vaginismus: Develops after a period of normal sexual function
    Severity Grading - Grade 1: Mildest form; patient can control muscle contractions with suggestions
    - Grade 2: Persistent muscle contraction despite suggestions during examination
    - Grade 3: Patient attempts to avoid examination by lifting or moving hips
    - Grade 4: Patient prevents examination by lifting hips, pulling back, and closing legs
    - Grade 5: Severe reactions such as tremors, hyperventilation, palpitations, crying, nausea, or even attacking the examiner (defined by Pacik)
    Primary Symptoms - Involuntary tightening of vaginal muscles during attempted penetration
    - Pain or burning sensation with penetration attempts
    - Fear and anxiety about penetration
    Secondary Symptoms - Avoidance of sexual activity
    - Relationship stress
    - Difficulty with gynecological exams or tampon use



    Management requires a holistic, multidisciplinary approach targeting both psychological and physical factors. Clinicians must adopt a compassionate, sensitive method, recognizing the emotional and physiological aspects influencing patient comfort and cooperation in treatment.


    Broad Principles of Management

    1. Comprehensive Evaluation

      • Obtain detailed Hx: gynecological, obstetric, sexual, and urological.
      • Conduct genital exam (external/internal), assessing for anomalies, scarring, or inflammation.
      • Approach pelvic exams gradually, prioritize patient comfort and consent, and be prepared to pause or reschedule as needed.

    2. Tailored, Multidisciplinary Approach

      • Behavioral Therapies: CBT for addressing anxiety, fear, and negative associations with intimacy.
      • Pelvic Floor Physical Therapy: Gradual muscle relaxation and control techniques.
      • Systematic Desensitization: Progressive vaginal dilator use, focusing on patient’s tolerance and goals.

    3. Patient Education & Communication

      • Provide open, stigma-free information on sexual health, normalizing discussion around vaginismus to reduce shame and embarrassment.
      • Support patient’s own goals (e.g., pain-free intercourse, tampon use, or comfortable exams).

    4. Partner Involvement & Sensate Focus

      • Involve partner (if applicable) in structured intimacy exercises to build trust, focusing on non-penetrative touch and reducing performance anxiety.

    5. Pharmacological Interventions (if indicated)

      • Topical Anesthetics (e.g., lidocaine) or Botulinum Toxin Injections in select cases to alleviate pain and muscle spasm.
      • Topical Estrogen: Beneficial in cases with vulvovaginal atrophy or dryness (especially peri-/postmenopausal).

    6. Consideration for Pregnant Patients

      • Recognize unique challenges in pregnant patients with vaginismus, ensuring supportive obstetric care to prevent avoidance due to past negative experiences or lack of provider understanding.

    7. Assisted Reproduction Options

      • For patients aiming for conception, provide information on assisted reproductive options where vaginismus hinders natural conception efforts.


    Women with vaginismus generally have a favorable prognosis, especially with appropriate treatment, which often leads to significant symptom improvement and greater sexual satisfaction. Success can depend on factors such as the condition’s duration, any coexisting psychological issues, and support from partners and healthcare providers. GPs play a key role in creating a supportive environment for open discussions on sexual health, helping to ensure timely diagnosis and effective treatment.



    **References:**

    1. Eserdağ et al. "Insights into the Vaginismus Treatment by Cognitive Behavioral Therapies: Correlation with Sexual Dysfunction Identified in Male Spouses of the Patients." *Journal of Family & Reproductive Health* (2021). doi:10.18502/jfrh.v15i1.6079
    2. Ferreira and Souza. "Botulinum Toxin for Vaginismus Treatment." *Pharmacology* (2012). doi:10.1159/000337383
    3. Marthasari et al. "Vaginismus and Infertility." *Indonesian Andrology and Biomedical Journal* (2020). doi:10.20473/iabj.v1i2.33
    4. Banaei et al. "Bio-Psychosocial Factor of Vaginismus in Iranian Women." *Reproductive Health* (2021). doi:10.1186/s12978-021-01260-2
    5. Muammar et al. "Management of Vaginal Penetration Phobia in Arab Women: A Retrospective Study." *Annals of Saudi Medicine* (2015). doi:10.5144/0256-4947.2015.120
    6. Ramanathan et al. "Common Pitfalls in the Management of Vaginismus in Couples With Subfertility in India." *Journal of Psychosexual Health* (2022). doi:10.1177/26318318221089600
    7. Demirci and Kabukçuoğlu. "‘Being a Woman’ in the Shadow of Vaginismus: The Implications of Vaginismus for Women." *Current Psychiatry Research and Reviews* (2020). doi:10.2174/2666082215666190917153811
    8. Çankaya and Aslantaş. "Determination of Sexual Attitude, Sexual Self-Consciousness, and Sociocultural Status in Women With and Without Lifelong Vaginismus: A Case-Control Study." *Clinical Nursing Research* (2022). doi:10.1177/10547738221103334
    9. Pereira et al. "Physiotherapy Protocol with Interferential Current in the Treatment of Vaginismus."
    10. Pacik et al. "Case Series: Redefining Severe Grade 5 Vaginismus." *Sexual Medicine* (2019). doi:10.1016/j.esxm.2019.07.006
    11. Çankaya and Aslantaş. "Determination of Dyadic Adjustment, Marriage and Sexual Satisfaction as Risk Factors for Women with Lifelong Vaginismus: A Case Control Study." *Clinical Nursing Research* (2021). doi:10.1177/10547738211046136
    12. Pacik and Geletta. "Vaginismus Treatment: Clinical Trials Follow-Up on 241 Patients." *Sexual Medicine* (2017). doi:10.1016/j.esxm.2017.02.002
    13. Zarski et al. "Efficacy of Internet-Based Guided Treatment for Genito-Pelvic Pain/Penetration Disorder: Rationale, Treatment Protocol, and Design of a Randomized Controlled Trial." *Frontiers in Psychiatry* (2018). doi:10.3389/fpsyt.2017.00260
    14. Pacik. "Vaginismus: Review of Current Concepts and Treatment Using Botox Injections, Bupivacaine Injections, and Progressive Dilation with the Patient Under Anesthesia." *Aesthetic Plastic Surgery* (2011). doi:10.1007/s00266-011-9737-5
    15. Achour et al. "Vaginismus and Pregnancy: Epidemiological Profile and Management Difficulties." *Psychology Research and Behavior Management* (2019). doi:10.2147/prbm.s186950







    Vaginismus

    Premature ejaculation (PE) is a prevalent male sexual dysfunction characterized by ejaculation that occurs before or shortly after vaginal penetration, leading to distress and dissatisfaction in sexual relationships. The condition affects approximately 20% to 30% of men at some point in their lives, making it a significant concern in primary care settings (Eid, 2023; Saitz & Şerefoğlu, 2016).


    The causes of PE can be summarised as


    Category Cause Description
    Psychological Factors Anxiety Particularly about sexual performance, leading to a cycle of distress that impairs sexual function.
    Stress General stress can exacerbate PE by affecting mental focus and physical responses.
    Depression Mood disorders influencing sexual desire and performance, contributing to PE.
    Relationship Problems Interpersonal issues increasing anxiety and reducing sexual satisfaction, leading to PE.
    Early Sexual Experiences or Trauma Past experiences impacting current sexual function through psychological associations. Past experiences impacting current sexual function through psychological associations.
    Strict Upbringing Regarding Sex May lead to guilt or anxiety during sexual activity, contributing to PE.
    Biological Factors Abnormal Hormone Levels ↑↓ Imbalances in thyroid hormones, prolactin, or testosterone affecting sexual function.
    Neurotransmitter Imbalance Particularly serotonin levels affecting ejaculatory control. Particularly serotonin levels affecting ejaculatory control.
    Inflammation or Infection Of the prostate or urethra causing increased sensitivity and PE.
    Erectile Dysfunction Fear of losing an erection may lead to rushing sexual activity, resulting in PE.
    Genetic Predisposition Family history indicating a genetic component to PE.
    Certain Neurological Conditions Conditions affecting the nervous system can impact ejaculatory control.
    Hypersensitivity of the Glans Penis Increased sensitivity leading to rapid ejaculation due to abnormal reflex pathways.
    Other Factors Substance Use Use of certain drugs or alcohol affecting sexual performance and control.
    Age and Experience Younger men or those with less sexual experience may be more prone to PE.
    Type of PE Lifelong (primary) or acquired (secondary); causes may differ between these types.


    Management - Quick summary


    Management Approach Details Notes
    Non-Pharmacological
    (First-line)
    Behavioral Therapies Techniques like the stop-start method and squeeze technique to enhance ejaculatory control. Includes stop-start and squeeze techniques; can improve control and confidence.
    Psychosexual Counseling Therapy addressing psychological factors such as anxiety and relationship issues. Helps reduce performance anxiety and improve communication between partners.
    Pelvic Floor Muscle Training Strengthening exercises to improve control over ejaculation.
    Pharmacological
    (Second-line)
    Selective Serotonin Reuptake Inhibitors (SSRIs) Medications that increase serotonin levels to delay ejaculation. Serotonin - **Dapoxetine** (only SSRI licensed for PE)
    - Others (paroxetine, sertraline, fluoxetine) used off-label
    - Side effects: nausea, dizziness
    Topical Anesthetics - Lidocaine or prilocaine creams/sprays
    - Reduce penile sensitivity
    - Available over-the-counter
    Tricyclic Antidepressants - **Clomipramine** used off-label
    - Can delay ejaculation
    - Monitor for side effects
    Combined Therapy Pharmacotherapy + Behavioral Techniques Combining medications with behavioral therapy may enhance effectiveness.
    Adjunctive Therapies - Mindfulness therapy
    - Cognitive Behavioral Therapy (CBT)
    - Traditional Chinese Medicine
    Treat Underlying Conditions Address Erectile Dysfunction Treat ED first if PE is secondary to it.
    Patient Education Communication Skills Improving dialogue with partner about needs and concerns. Educate about normal sexual function; set realistic expectations.


    **References:**

    1. **Asimakopoulos, A., Miano, R., Agrò, E., Vespasiani, G., & Spera, E.** (2012). Does current scientific and clinical evidence support the use of phosphodiesterase type 5 inhibitors for the treatment of premature ejaculation? A systematic review and meta-analysis. *Journal of Sexual Medicine*, **9**(9), 2404-2416. [https://doi.org/10.1111/j.1743-6109.2011.02628.x](https://doi.org/10.1111/j.1743-6109.2011.02628.x)

    2. **Ayribas, B., & Toprak, T.** (2020). New approach to patients with premature ejaculation: Do social cognition and attachment profiles play a role in premature ejaculation? *Andrologia*, **53**(1), e13882. [https://doi.org/10.1111/and.13882](https://doi.org/10.1111/and.13882)

    3. **Bagcioglu, E., Efe, E., Bahçeci, B., & Söylemez, H.** (2013). Prematür ejakülasyon hastalarında mizaç ve karakter farklılıkları. *Nöro Psikiyatri Arşivi*, **50**(4), 332-336. [https://doi.org/10.4274/npa.y6443](https://doi.org/10.4274/npa.y6443)

    4. **Chen, Z., Yuan, M., Ma, Z., Wen, J., Wang, X., Zhao, M., ... & Guo, L.** (2020). Significance of piezo-type mechanosensitive ion channel component 2 in premature ejaculation: An animal study. *Andrology*, **8**(5), 1347-1359. [https://doi.org/10.1111/andr.12779](https://doi.org/10.1111/andr.12779)

    5. **Cooper, K., James, M., Kaltenthaler, E., Dickinson, K., Cantrell, A., Wylie, K., ... & Hood, C.** (2015). Behavioral therapies for management of premature ejaculation: A systematic review. *Sexual Medicine*, **3**(3), 174-188. [https://doi.org/10.1002/sm2.65](https://doi.org/10.1002/sm2.65)

    6. **Doğan, K.** (2023). The effects of behavioral therapy given to men with premature ejaculation on symptoms and their partners’ sexual functioning and sexual quality of life. *Journal of Health Sciences and Medicine*, **6**(5), 974-980. [https://doi.org/10.32322/jhsm.1341975](https://doi.org/10.32322/jhsm.1341975)

    7. **Doğan, K., & Keçe, C.** (2023). Comparison of the results of stop-start technique with stop-start technique and sphincter control training applied in premature ejaculation treatment. *PLOS ONE*, **18**(8), e0283091. [https://doi.org/10.1371/journal.pone.0283091](https://doi.org/10.1371/journal.pone.0283091)

    8. **Eid, A.** (2023). Evaluation of serum prolactin and testosterone in premature ejaculation patients. *Journal of Advances in Medicine and Medical Research*, **35**(20), 222-241. [https://doi.org/10.9734/jammr/2023/v35i205193](https://doi.org/10.9734/jammr/2023/v35i205193)

    9. **Guo, J., Wang, F., Zhou, Q., Qian, G., Gao, Q., Zhang, R., ... & Jannini, E.** (2020). Safety and efficacy of traditional Chinese medicine, *Qiaoshao* formula, combined with dapoxetine in the treatment of premature ejaculation: An open-label, real-life, retrospective multicentre study in Chinese men. *Andrologia*, **53**(1), e13915. [https://doi.org/10.1111/and.13915](https://doi.org/10.1111/and.13915)

    10. **Jiang, M., Yan, G., Deng, H., Liang, H., Lin, Y., & Zhang, X.** (2019). The efficacy of regular penis-root masturbation versus Kegel exercise in the treatment of primary premature ejaculation: A quasi-randomised controlled trial. *Andrologia*, **52**(1), e13473. [https://doi.org/10.1111/and.13473](https://doi.org/10.1111/and.13473)

    11. **Li, Y., Duan, Y., Yu, X., Wang, J., Yao, Z., Gong, X., ... & Guo, J.** (2019). Traditional Chinese medicine on treating premature ejaculation. *Medicine*, **98**(18), e15379. [https://doi.org/10.1097/MD.0000000000015379](https://doi.org/10.1097/MD.0000000000015379)

    12. **Nagabhairava, M.** (2024). Comparison of pain control between lidocaine and prilocaine spray (TEMPE) versus lidocaine gel in the treatment of premature ejaculation: A prospective randomized controlled trial in a tertiary care centre. *International Journal of Research in Medical Sciences*, **12**(5), 1601-1605. [https://doi.org/10.18203/2320-6012.ijrms20240944](https://doi.org/10.18203/2320-6012.ijrms20240944)

    13. **Saitz, T., & Şerefoğlu, E.** (2016). The epidemiology of premature ejaculation. *Translational Andrology and Urology*, **5**(4), 409-415. [https://doi.org/10.21037/tau.2016.05.11](https://doi.org/10.21037/tau.2016.05.11)

    14. **Santtila, P., Jern, P., Westberg, L., Walum, H., Pedersen, C., Eriksson, E., ... & Sandnabba, N.** (2010). The dopamine transporter gene (DAT1) polymorphism is associated with premature ejaculation. *Journal of Sexual Medicine*, **7**(4 Pt 1), 1538-1546. [https://doi.org/10.1111/j.1743-6109.2009.01696.x](https://doi.org/10.1111/j.1743-6109.2009.01696.x)

    15. **Shindel, A., Althof, S., Carrier, S., Chou, R., McMahon, C., Mulhall, J., ... & Sharlip, I.** (2022). Disorders of ejaculation: An AUA/SMSNA guideline. *The Journal of Urology*, **207**(3), 504-512. [https://doi.org/10.1097/JU.0000000000002392](https://doi.org/10.1097/JU.0000000000002392)

    16. **Waldinger, M.** (2014). Pharmacotherapy for premature ejaculation. *Current Opinion in Psychiatry*, **27**(6), 400-405. [https://doi.org/10.1097/YCO.0000000000000096](https://doi.org/10.1097/YCO.0000000000000096)

    17. **Zadeh, S.** (2023). Effects of transcranial direct current stimulation and behavior therapy using the start-stop method on the treatment of men with sexual disorder premature ejaculation. *Journal of Clinical Research in Paramedical Sciences*, **12**(2). [https://doi.org/10.5812/jcrps-140182](https://doi.org/10.5812/jcrps-140182)

    18. **Çayan, S., & Şerefoğlu, E.** (2014). Advances in treating premature ejaculation. *F1000Prime Reports*, **6**, 55. [https://doi.org/10.12703/P6-55](https://doi.org/10.12703/P6-55)


    Premature ejaculation

    Dyspareunia, defined as persistent pain during or after sexual intercourse, is a multifactorial cpndition. The causes of dyspareunia can be broadly categorized into physical, psychological, and situational factors, each contributing to the patient's experience of pain.


    Category Cause Description
    Physical Causes Endometriosis Growth of endometrial tissue outside the uterus Growth of endometrial tissue outside the uterus causing pelvic pain, dysmenorrhea, and deep dyspareunia.
    Vulvodynia and Vestibulodynia Chronic pain conditions affecting the vulvar area Chronic pain or discomfort of the vulvar area leading to superficial dyspareunia.
    Vaginal Atrophy Thinning of the vaginal walls due to decreased estrogen levels Thinning and drying of the vaginal walls due to decreased estrogen levels, common in postmenopausal women, causing pain during intercourse.
    Infections Includes vaginitis, urinary tract infections, yeast infections, and STIs like herpes, causing inflammation and pain during intercourse.
    Pelvic Floor Dysfunction Hypertonic pelvic floor muscles leading to pain during penetration due to muscle spasms or tightness.
    Skin Disorders Conditions such as lichen planus, lichen sclerosus, and psoriasis causing vulvar inflammation and discomfort during sex.
    Pelvic Inflammatory Disease Infection of the upper genital tract causing deep pelvic pain and dyspareunia.
    Psychological Factors Emotional Distress Stress, anxiety, and depression increasing muscle tension and pain perception during intercourse.
    History of Trauma Past sexual abuse or traumatic experiences contributing to pain due to psychological and physiological responses.
    Situational Factors Postpartum Changes Perineal trauma or anatomical changes after childbirth leading to dyspareunia in the postpartum period.
    Surgical History Previous pelvic surgeries like hysterectomy causing scar tissue or changes in anatomy resulting in painful intercourse.
    Inadequate Lubrication Often due to hormonal changes or insufficient arousal, leading to friction and discomfort during sex.


    **References:**

    1. **Alimi, Y., Iwanaga, J., Oskouian, R., Loukas, M., & Tubbs, R.** (2018). The clinical anatomy of dyspareunia: a review. *Clinical Anatomy*, **31**(7), 1013-1017. [https://doi.org/10.1002/ca.23250](https://doi.org/10.1002/ca.23250)
    2. **Corden, C.** (2013). Causes and management of dyspareunia. *InnovAiT: Education and Inspiration for General Practice*, **6**(2), 66-75. [https://doi.org/10.1177/1755738012470253](https://doi.org/10.1177/1755738012470253)
    3. **Eisenberg, V., Weil, C., Chodick, G., & Shalev, V.** (2017). Epidemiology of endometriosis: a large population-based database study from a healthcare provider with 2 million members. *BJOG: An International Journal of Obstetrics & Gynaecology*, **125**(1), 55-62. [https://doi.org/10.1111/1471-0528.14711](https://doi.org/10.1111/1471-0528.14711)
    4. **Farfaras, A., Pierrakos, G., Pateras, I., Skolarikos, P., Wen, S., & Sarris, M.** (2014). Endometriosis: does surgery offer long-term improvement in quality of life? *Journal of Endometriosis and Pelvic Pain Disorders*, **6**(2), 106-111. [https://doi.org/10.5301/je.5000187](https://doi.org/10.5301/je.5000187)
    5. **Kj, W., S, I., Joseph, K., Kb, S., & Yong, P.** (2019). Dyspareunia in their own words: a comprehensive qualitative description of endometriosis-associated sexual pain. [https://doi.org/10.1101/19005793](https://doi.org/10.1101/19005793)
    6. **Leeners, B., Hengartner, M., Ajdacic-Gross, V., Rössler, W., & Angst, J.** (2015). Dyspareunia in the context of psychopathology, personality traits, and coping resources: results from a prospective longitudinal cohort study from age 30 to 50. *Archives of Sexual Behavior*, **44**(6), 1551-1560. [https://doi.org/10.1007/s10508-014-0395-y](https://doi.org/10.1007/s10508-014-0395-y)
    7. **Morris, C., Briggs, C., & Navani, M.** (2021). Dyspareunia. *InnovAiT: Education and Inspiration for General Practice*, **14**(10), 607-614. [https://doi.org/10.1177/17557380211030299](https://doi.org/10.1177/17557380211030299)
    8. **Orr, N., Wahl, K., Joannou, A., Hartmann, D., Valle, L., Yong, P., & Renzelli-Cain, R.** (2019). Deep dyspareunia: review of pathophysiology and proposed future research priorities. *Sexual Medicine Reviews*, **8**(1), 3-17. [https://doi.org/10.1016/j.sxmr.2018.12.007](https://doi.org/10.1016/j.sxmr.2018.12.007)
    9. **Schnittka, E., Lanpher, N., & Patel, P.** (2022). Postpartum dyspareunia following continuous versus interrupted perineal repair: a systematic review and meta-analysis. *Cureus*. [https://doi.org/10.7759/cureus.29070](https://doi.org/10.7759/cureus.29070)
    10. **Streicher, L.** (2023). Diagnosis, causes, and treatment of dyspareunia in postmenopausal women. *Menopause: The Journal of the North American Menopause Society*, **30**(6), 635-649. [https://doi.org/10.1097/gme.0000000000002179](https://doi.org/10.1097/gme.0000000000002179)
    11. **Yong, P., Mui, J., Allaire, C., & Williams, C.** (2014). Pelvic floor tenderness in the etiology of superficial dyspareunia. *Journal of Obstetrics and Gynaecology Canada*, **36**(11), 1002-1009. [https://doi.org/10.1016/s1701-2163(15)30414-x](https://doi.org/10.1016/s1701-2163(15)30414-x)

    Dyspareunia

    AktDemo
    Take a demo of Akt revision and enhance your learning
    experience with us.

    Fueling Growth: Where Content and Traffic Thrive!

    +

    Charts

    +

    Active monthly Users

    +

    AKT MCQ's

    count down

    Plans & Pricing

    Unlocking Primary Care Education: Making it Accessible and Affordable

    Free Trial

    £0
    • tick-checkbox  No Cards Required
    • tick-checkbox  See all Charts and Tables
    • tick-checkbox  All Webinar
    • tick-checkbox  Practice MCQ's
    • tick-checkbox  Cancel Any time
    • tick-checkbox  No auto-pay commitment

    Monthly

    £4.99
    • tick-checkbox  Access all content
    • tick-checkbox  See all Charts and Tables
    • tick-checkbox  All Webinar
    • tick-checkbox  Cancel Any time
    • tick-checkbox  AKT MCQ's

    Free Access with books

    Buy any book-12 month access included

    Shop Now

    Frequently Asked Question


    What is A4Medicine?
    Who is A4Medicine for?
    What resources are available on A4Medicine?
    How can I access the resources on A4Medicine?
    Is A4Medicine a trusted source of information?
    Can I cancel my subscription or request a refund?
    Does A4Medicine share my information with any third parties?
    What payment options are available on A4Medicine's website?
    Is my data safe on A4Medicine's website?

    Our   Testimonials

    what client say about us?